Aureka Biotech Raises $100M Series B for Biological Foundation Models
Aureka Biotechnologies closed a $100 million Series B to build a closed-loop AI infrastructure that integrates foundation models with high-throughput experiments. The funding aims to advance de novo molecular design and biological structure prediction, marking a shift from AI-as-tool to AI-as-platform in biopharma R&D.